Please assess the completion status of the following clinical trial:

Trial Title: [124I]FIAU PET-CT Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients \>/= 18 years on the day of signing consent.~2. A diagnosis of diabetes mellitus, type I or II, as evidenced either by HbA1c\>6.5% or receipt of antidiabetic medication at time of enrollment.~3. Ability to provide informed consent~4. An inframalleolar ulcer of perfusion, extent/size, depth/tissue loss, infection and sensation (PEDIS) grade 2 or 3. At the discretion of the Investigator, patients with PEDIS grade 4 infections may be included if they are sufficiently stable.~5. For females of childbearing potential, a negative urine pregnancy test on the day of dosing.~6. For females of childbearing potential, a willingness to use 2 methods of contraception for 30 days after receiving \[124I\]FIAU.~7. Ability to return for all study assessments.~8. Clinically euthyroid, or on stable thyroid replacement therapy.~Exclusion Criteria:~1. Patients who ar unable to comply with study requirements.~2. Indication, in the opinion of the principal Investigator for urgent surgery that would preclude the time needed for PET-CT scanning, or clinical instability that precludes PET-CT scanning.~3. History of an inherited mitochondrial disorder (eg. Leber's hereditary neuropathy, neuropathy, ataxia, retinitis pigmentosa and ptosis \[NARP\], myoneurogenic gastrointestinal encephalopathy \[MNGIE\], myocolonic epilepsy with ragged red fibers \[MERFF\] and mitochondrial myopathy, encephalomyopathy, lactic acidosis and stroke-like syndrome \[MELAS\])~4. Alanine aminotransferase (ALT)\>5x Upper Limit of Normal (ULN) OR aspartate aminotransferase (AST) \>5x ULN.~5. Body mass that exceeds the rating of the CT table.~6. Hypersensitivity to iodine.~7. Pregnant or breast-feeding.~8. Any condition that would put the patient at unreasonable risk in the opinion of the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [124I]FIAU (Type: EXPERIMENTAL): Single intravenous injection of \[124I\]FIAU in patients with diabetic foot infection

Based on this trial design, predict the completion outcome and termination type (if applicable).